Influence of tumor extent on central lymph node metastasis in solitary papillary thyroid microcarcinomas: a retrospective study of 1092 patients

Papillary thyroid microcarcinoma (PTMC) is defined by the World Health Organization as a malignant tumor with diameter ≤1 cm [1]. In recent years, owing to the wide application of high-resolution and contrast-enhanced ultrasonography (US) of the thyroid, as well as ultrasonography-mediated fine needle aspiration biopsy (FNA), along with improved histopathological criteria, increasing numbers of patients have been diagnosed with PTMC [2, 3]. According to the current literature, the prevalence of solitary PTMC, that is, a single lesion in the thyroid gland, ranges between 18 and 79.7% among PTMC [4‐6]. The thyroid capsule is composed of varying proportions of fibrous and adipose tissues and is discontinuous in the anterior midline of the isthmus [7]. As described in the American Joint Commission on Cancer staging system (7th edition), the T stage of PTMC varies with the relationship between the tumor and the thyroid capsule: tumor limited to the thyroid is T1a while PTMC with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues) is T3. However, there are three cases of their relationship in clinical work: tumor limited to the thyroid (including primary tumor adjacent to the thyroid capsule), capsule invasion (no capsular penetration), and capsular penetration with extension into the sternothyroid muscle or perithyroidal soft tissue (extrathyroidal extension). Then, whether capsule invasion of PTMC belongs to T1a or T3 and whether we should choose the same operation for PTMC with capsule invasion and extrathyroidal extension is a problem that we clinicians are confused.

Meanwhile, the treatment of PTMC may vary from follow-up to a total thyroidectomy and lymph node dissection with or without radioactive iodine treatment, and the choice of surgical method partly depends on the T stage of the tumor. Although PTMC is believed to be an indolent disease, the reported incidence of central lymph node metastasis (CLNM) associated with PTMC has been reported to be as high as 41.3% [8], and CLNM is known to be related to poor prognosis and locoregional recurrence [9]. However, prophylactic central lymph node dissection (CLND) has been reported to increase postoperative morbidity (transient hypocalcemia or recurrent laryngeal nerve paralysis) [10, 11], and the use of total thyroidectomy (TT) plus CLND is thus debated for PTMC, because prophylactic CLND may have little prognostic benefit and increase postoperative morbidity [12]. Accordingly, it is important to identify the risk factors for CLNM so that appropriate clinical decisions regarding CLND can be made.

With this in mind, the present study was designed to explore whether capsule invasion belongs to the minimal extrathyroid extension and identify the risk factors associated with CLNM in PTMC by retrospectively investigating the effect of tumor extent and other factors on central lymph node metastasis in PTMC.

The clinicopathological characteristics of the 1092 enrolled patients are listed in Table 1. The mean age was 45.30 ± 10.33 years (range, 19–87 years), and there were 900 women (82.4%) and 192 men (17.6%). The median tumor size was 0.53 ± 0.23 cm (range, 0.05–1 cm); the primary tumor size was ≤5 mm in 602 patients and >5 mm in 490 patients. The tumor was located within the thyroid capsule in 699 (64.0%) cases, had invaded the capsule in 355 (30.7%) cases, and had penetrated the capsule and extended into the sternothyroid muscle or perithyroidal soft tissue in 58 (5.3%) cases. Lymphocytic thyroiditis was found in 129 patients. CLNM was found in 300 (27.4%) patients (Table 1), while contralateral lymph node metastasis accounted for 21.7% in patients with CLNM (data not shown).

According to the univariate analysis (Table 2), the tumor extent was significantly correlated with CLNM (P < 0.001). Male sex, age <45 years, and tumor diameter >5 mm were also significant predictive factors for CLNM (P < 0.05). In contrast, the histological subtype did not predict CLNM in solitary PTMC. Meanwhile, lymphocytic thyroiditis was revealed to be a protective factor against CLNM in patients with solitary PTMC.

The analysis of the impact of the tumor extent on CLNM, with tumors limited to the thyroid as the reference, is shown in Table 3. The analysis showed that the risk of developing CLNM increased with capsule invasion (OR, 1.446; 95% CI, 1.082–1.931) and extracapsular extension (OR, 3.440; 95% CI, 1.997–5.925). Multivariate analysis revealed that while capsule invasion (P = 0.223) was not a statistically significant predictor of CLNM, extracapsular extension (P < 0.001) was indeed a statistically significant independent risk factor. In addition, male sex (OR, 2.072; P < 0.001), tumor size >5 mm (OR, 2.356; P < 0.001), and age <45 years (OR, 2.302; P < 0.001) were independent predictors of CLNM (Table 4).

Among 1092 patients, transient hypocalcemia developed in 12 patients (1.09%) and 1 patients (0.09%) had permanent hypoparathyroidism. Recurrent laryngeal nerve injury developed in 17 patients (1.56%) and recovered within 6 months, and no cases experienced permanent recurrent laryngeal nerve paralysis. Chyle leakage occurred in 2 patients (0.2%). Chyle leakage was controlled with a fat-free diet and local compression. Postoperative hematoma developed in 5 patients (0.5%) and was controlled by reoperation.

According to the American Joint Commission on Cancer staging system (7th edition), in papillary thyroid microcarcinomas, T1a stage tumors are defined as tumors ≤1 cm without extrathyroidal extension, while any tumors with minimal extrathyroid extension (e.g., extension into the sternothyroid muscles or perithyroidal soft tissues) are classified as T3 stage tumors. However, it has not been decided whether PTMC with capsule invasion should be classified as stage T1a or T3. Because the recommendations for clinical treatment vary according to the TNM stage, accurate T categorization is very important. Several recent studies have described the association of capsule invasion and/or extracapsular extension with CLNM in patients with PTMC [6, 13]; in comparison, our study focused only on solitary PTMC and contained the largest number of patients and all patients underwent TT and CLND.

In the present study, multivariate analysis showed that extrathyroidal extension was independent predictor of CLNM in solitary PTMCs. Previous studies have also reported that extrathyroidal extension was associated with CLNM in patients with PTMC [3, 6, 13, 14]. Our study reveal that capsule invasion and tumor limited to the thyroid were not identified as independent risk factor for CLNM in solitary PTMC; this might indicate that capsule invasion does not belong to the minimal extrathyroid extension category and that tumors ≤1 cm with capsule invasion might be classified as T1a.

The incidence of CLNM in patients with clinically node-negative PTMC has been reported from 31 to 64% [6, 13, 15], and the presence of CLNM is closely associated with prognosis and is a key factor for tumor staging [9, 16]. However, the use of routine prophylactic CLND for PTMC is controversial due to the high risk of postoperative morbidity and the limited prognostic benefits [9, 17]. Moreover, CLNM cannot be detected clinically because of the local anatomy of the level VI lymph nodes [16]. In our study, 300 patients had cervical lymph node metastases, representing 27.5% of all 1092 patients, which was lower than previous studies [6, 13, 15]. This large range in the prevalence of CLNM may be due to differences that we focused on solitary PTMC only. In this study, we found that extrathyroidal extension, male sex, age <45 years, and tumor size >5 mm were risk factors for CLNM.

Younger age (age <45 years) was associated with CLNM in this study. However, it is unclear about its prognostic value in PTMC [13, 18]. Previous studies have also reported that age <45 years was associated with CLNM in PTMC [6]. Generally, CLNM is known to increase with tumor size, and tumor size >5 mm was an independent predictor of CLNM in my research, which is in agreement with a previous report [15]. In addition, consistent with some previous researches [6, 13, 15], gender was a risk factor for CLNM in my study.

Moreover, lymphocytic thyroiditis was shown to protect patients with solitary PTMC against CLNM in the univariate analysis, which was consistent with the findings of previous studies on papillary thyroid carcinoma [19, 20]. This may be explained from the following two aspects [21]: On one hand, the autoimmune response may destroy cancer cells expressing thyroid-specific antigens, thereby preventing cancer progression. On the other hand, if lymphocytic thyroiditis leads to atrophy and fibrosis of the thyroid gland, there may be associated damage to the surrounding lymphatic vessels, which may prevent lymphatic spread and reduce the likelihood of CLNM [20].

The treatment of PTMC is a contentious subject. In this study, our results supported the notion that a more radical surgical treatment is appropriate treatment strategy for PTMCs with extrathyroidal extension, male sex, tumor size, and age <45 years. This conclusion was based on the following considerations: first, as preoperative assessment is limited, bilateral cancer and multifocality of the thyroid might be assessed as a single focus; second, among patients with CLNM, contralateral lymph node metastasis accounted for 21.7% in our study. Morbidity of complications is low when TT plus CLND is performed by experienced surgeons in this study and CLND did not increase permanent morbidities obviously [14]. In addition, morbidity is relatively high when reoperation is performed on patients with regional recurrence in the central compartment. Moreover, TT plus CLND is beneficial for postoperative follow-up and radioactive iodine (131I) thyroid remnant ablation and is associated with a low recurrence rate. Thus, a more radical surgical treatment should be considered for PTMCs with high-risk factors.

In conclusion, extrathyroid extension is a significant predictor of CLNM in PTMC. Our findings suggest that capsule invasion may not belong to the minimal extrathyroid extension category. Meanwhile, our results are useful in identifying PTMC with extrathyroid extension, male sex, tumor size >5 mm, and age <45 years, which are more likely to have CLNM, and on the basis of this, we could choose to perform more radical treatment in patients with potentially aggressive tumors. In addition, our study revealed that coexistent lymphocytic thyroiditis protects patients with PTMC from CLNM.